Notice how they are discussing how to make pluripotent stem cells into a product. Cozy collaboration if you ask me.
Pluripotent Stem Cells in Translation: Early Decisions
The National Institutes of Health and the Food and Drug Administration are collaborating on a series of workshops on moving pluripotent stem cell therapies into the clinic.
The first two day workshop, “Pluripotent Cells in Translation: Early Decisions,” is scheduled for March 21 and 22 at Lister Hill Auditorium on the NIH campus in Bethesda, Maryland. The first day will cover pluripotency and its challenges, sources of pluripotent cells, and stem cell banks; the second day will cover making pluripotent stem cells into a product, product characterization, and emerging technologies.
The meeting has participation from industry, academic and clinical scientists, the FDA, and the NIH. Space is limited, and registration is required at the link below. The meeting will also be webcast at a link to be announced later.
Pluripotent Stem Cells in Translation: Early Decisions
The National Institutes of Health and the Food and Drug Administration are collaborating on a series of workshops on moving pluripotent stem cell therapies into the clinic.
The first two day workshop, “Pluripotent Cells in Translation: Early Decisions,” is scheduled for March 21 and 22 at Lister Hill Auditorium on the NIH campus in Bethesda, Maryland. The first day will cover pluripotency and its challenges, sources of pluripotent cells, and stem cell banks; the second day will cover making pluripotent stem cells into a product, product characterization, and emerging technologies.
The meeting has participation from industry, academic and clinical scientists, the FDA, and the NIH. Space is limited, and registration is required at the link below. The meeting will also be webcast at a link to be announced later.